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TheTcell receptor (TCR) andCD8bindpeptide-major
histocompatibility complex (pMHC) glycoproteins to
initiate adaptive immune responses, yet the trimolec-
ular binding kinetics at the T cell membrane is
unknown. By using a micropipette adhesion fre-
quency assay, we show that this kinetics has two
stages. The first consists of TCR-dominant binding
to agonist pMHC. This triggers a second stage con-
sisting of a step increase in adhesion after a one
second delay. The second-stage binding requires
Src family kinase activity to initiate CD8 binding to
the same pMHC engaged by the TCR. This induced
trimeric-cooperative interaction enhances adhesion
synergistically to favor potent ligands, which further
amplifies discrimination. Our data reveal a TCR-CD8
positive-feedback loop involved in initial signaling
steps that is sensitive to a single pMHC is rapid,
reversible, synergistic, and peptide discriminative.
INTRODUCTION
Antigen recognition by the T cell is central to its development and
activation. Together with its coreceptor, the T cell receptor (TCR)
discriminates various peptide-major histocompatibility complex
(pMHC) ligands, e.g., peptides that differ by even a single amino
acid, to differentially trigger intracellular signals, leading to awide
range of T cell responses (Davis et al., 2007; Evavold and Allen,
1991; Evavold et al., 1993). Related to this specificity is an exqui-
site sensitivity; theTcells arecapableofdetectinga single agonist
pMHC to initiate transient calcium fluxes (Irvine et al., 2002; Purb-
hoo et al., 2004). Furthermore, these responses are remarkably
fast: TCR microclusters (Campi et al., 2005; Yokosuka et al.,
2005), intracellular calcium fluxes, and phosphorylation of linker
for activation of T cells (LAT) are observed within a few seconds
upon TCR contact with pMHC (Huse et al., 2007).The coreceptor on cytotoxic T cells is CD8, which binds the a3
conservative domain of the MHC without peptide contact. This
binding property is distinct from TCR, which binds the a1 and
a2 domains as well as the peptide (Gao et al., 1997; Kern
et al., 1998). CD8 has much lower affinity than TCR for agonist
pMHC (Garcia et al., 1996; Wyer et al., 1999), suggesting that
CD8 binding mostly helps weak ligands that have low TCR affin-
ities (Laugel et al., 2007). CD8 associates with the Src family
kinase p56lck (Lck) (Davis et al., 2003; Palacios and Weiss,
2004) and its absence impairs T cell responses (Delon et al.,
1998; Xu et al., 2001). However, it remains unclear whether
and, if so, how CD8 facilitates peptide discrimination.
It is also unclear how pMHC binds TCR and CD8, e.g.,
concurrently, sequentially, independently, or cooperatively. It
has been proposed that binding of one receptor (CD8 or TCR)
holds the ligand (MHC) to an optimal configuration, thereby
accelerating the association of the other receptor (TCR or
CD8) to MHC (Gakamsky et al., 2005; Gao et al., 2002; Pecht
and Gakamsky, 2005). Alternatively, coengagement of both
TCR and CD8 with pMHC may stabilize the trimolecular bond,
thereby decelerating the dissociation of either or both
receptors (Campanelli et al., 2002; Garcia et al., 1996; Norment
et al., 1988). A surface plasmon resonance study found that
CD8 enhances the TCR-pMHC interaction by reducing the off-
rate (Garcia et al., 1996). However, another study found that
CD8 and TCR bind pMHC independently and that the TCR-
pMHC interaction is unaffected by the presence of CD8 (Wyer
et al., 1999). Studies with pMHC tetramers indicate that CD8
plays a direct or indirect role in pMHC binding (Daniels and
Jameson, 2000; Wooldridge et al., 2003). However, a major
limitation of these studies is that they measure binding of
soluble molecules in a fluid phase, i.e., three-dimensional (3D)
binding. In reality, pMHC on an antigen-presenting cell (APC)
binds TCR and/or CD8 on a T cell at the cross-junctional inter-
face, i.e., two-dimensional (2D) binding, which may be impacted
by the cellular environment (Huang et al., 2007, 2010; Huppa
et al., 2010).
We recently used mechanically based 2D assays with single-
bond sensitivity and subsecond temporal resolution to measureImmunity 34, 13–23, January 28, 2011 ª2011 Elsevier Inc. 13
Figure 1. Micropipette Adhesion Frequency Assay
(A) Micrograph of the micropipette assay. A T cell (left) was aspirated by
a pipette and aligned with a pMHC-coated RBC held stationary by another
pipette (right) (see Movie S1).
(B) Schematics of TCR and CD8 expressed on a T cell (left) and of pMHC
coated on a RBC via biotin-streptavidin coupling (right).
(C) Specificity controls at contact duration of 0.25 s (solid bars) or 5 s (open
bars) of adhesion frequencies between OT1 T cells and unmodified RBCs, bio-
tinylated RBCs without coating, biotinylated RBCs coated with BSA, null
pMHC-I (VSV:H-2Kb), pMHC-II (MOG:I-Ab), or agonist pMHC-I (OVA:H-2Kb),
or between MOGCD4+ T cells and biotinylated RBCs coated with OVA:H-2Kb.
Each T cell-RBC pair was tested repeatedly for 50 contact-retract cycles at
a given contact duration to estimate an adhesion frequency, and 3–5 cell pairs
were tested for each t to calculate a mean Pa ± SEM. See also Movie S1.
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TCR-CD8 Cooperation Amplifies pMHC Discriminationthe bimolecular interactions of a panel of pMHC ligands with the
CD8 (Huang et al., 2007) or TCR (Huang et al., 2010) on the T cell
membrane. Here we extend these studies to situations that allow
TCR-pMHC-CD8 trimolecular interactions and show them to be
cooperative upon induction. This induced TCR-CD8 cooperation
enhanced adhesion synergistically to favor potent ligands, which
amplified discrimination.14 Immunity 34, 13–23, January 28, 2011 ª2011 Elsevier Inc.RESULTS
To measure 2D interactions, a CD8+ T cell (Figure 1A, left)
expressing either OT1 or F5 TCR (Figure 1B, left) was aspirated
by a micropipette and moved in and out of contact with a red
blood cell (RBC, Figure 1A, right) bearing pMHC (Figure 1B, right)
held stationary by an apposing micropipette with a controlled
duration and area. The RBC served not only as a surrogate
APC but also as an adhesion sensor because its membrane
would be stretched by (a) molecular bond(s) on T cell retraction
(Movie S1 available online). Each contact resulted in a binary
adhesion score (0 or 1) and its average over 50 contacts of the
same duration t gives an adhesion frequency Pa, which is
specific (Figure 1C).
TCR-pMHC-CD8 Trimolecular Interaction Proceeds
in Two Stages
Plots of Pa versus t exhibited two stages, starting with a low
plateau and jumping to a highplateau after1 swith a<0.1 s tran-
sient phase before each equilibrium (Figures 2A and 2B, closed
square), indicating rapid kinetics for both stages (Chesla et al.,
1998). This two-stage kinetics, observed for bothOT1 (Figure 2A,
closed square) and F5 (Figure 2B, closed square) T cells interact-
ing with RBCs bearing the appropriate agonists at both 25C and
37C (Figures 2C and 2D), was distinct from the single-stage
kinetics previously observed for the TCR-pMHC (Huang et al.,
2010) and pMHC-CD8 (Huang et al., 2007) bimolecular interac-
tions. We used selective inhibition to dissect the respective
contributions of TCR and CD8 to the two-stage curve. Anti-TCR
completely blocked adhesion (Figures 2A and 2B, open triangle).
This TCR requirement was consistent with the low CD8-effective
2D affinities (106 and <108 mm4, for H-2Kb and H-2Db,
respectively) (Huang et al., 2007) and the low MHC densities
(25 H-2Kb/mm2 and 14 H-2Db/mm2) used. Based on the expres-
sions onOT1 and F5 T cells (250 and 426CD8/mm2, respectively),
CD8 was predicted to contribute 2% and <0.0074% adhesion
frequencies only (Experimental Procedures, Equations 1 and 2).
By comparison, the respective effective 2D affinities of the OT1
and F5 TCR were 0.5 and 2.8 3 104 mm4 for ovalbumin
(OVA):H-2Kb and influenza virus nucleoprotein (NP68):H-2Db,
respectively, as calculated from the first plateau Pa and TCR
densities (210 and 62 mm2 on OT1 and F5 T cells). These results
suggest that the first-stage curve is dominated by TCR-pMHC
binding with negligible pMHC-CD8 contribution.
By comparison, the CD8-blocking mAb CT-CD8a eliminated
the adhesion increment in the second stage but did not affect
the first stage, resulting in single-stage curves (Figures 2A and
2B, open circle). The OT1 curve was similar to that obtained
with an MHC mutant (Figure 2A, open diamond). This mutant
substituted the a3 domain in the wild-type mouse H-2Kb with
the a3 domain of human HLA-A2 (H-2Kba3A2) to abrogate the
binding of mouse CD8 (Huang et al., 2010). The use of CT-
CD8a Fab produced the same effect as whole antibody
(Figure S1), excluding crosslinking as the cause of inhibition.
Although these data demonstrate the requirement of CD8 for
the second-stage adhesion increment, the complete abrogation
of adhesion by anti-TCR excludes the independent concurrent
binding model (Zhu and Williams, 2000) of generating the
second stage by simply adding pMHC-CD8 bonds to the same
Figure 2. Two-Stage Kinetics of TCR-pMHC-CD8
Trimolecular Interaction
(A and B)Pa versus t data (points) of OT1 (A) or F5 (B) T cells
interacting with RBCs bearing 25 OVA:H-2Kb/mm2 (A) or 14
NP68:H-2Db/mm2 (B) in the absence (closed square) or
presence of anti-CD8 (open circle) or anti-TCR (open
triangle). Also included in (A) are data for OT1 T cells inter-
acting with RBCs bearing 25 OVA:H-2Kba3A2/mm2 (open
diamond). Curves are trend lines.
(C and D) Pa versus t data of OT1 (C) or F5 (D) T cells inter-
acting with RBCs bearing 12 OVA:H-2Kb/mm2 or 14
NP68:H-2Db/mm2, respectively, at 25C (open square) or
37C (open circle).
Representative data (measured by the same method as
that in Figure 1) of three repeated experiments are shown.
See also Figure S1.
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TCR-CD8 Cooperation Amplifies pMHC DiscriminationTCR-pMHCbondsas in the first stage (Experimental Procedures,
Equation 3). Furthermore, to attribute the second-stage adhesion
increment to pMHC-CD8 binding alone would require 40- and
>10,000-fold higher CD8 affinities for H-2Kb and H-2Db, respec-
tively, than thosemeasured in theabsenceofTCRbinding (Huang
et al., 2007). Nevertheless, the increased contribution to the
second stage identified aCD8-dependent upregulated functional
state. TCR binding was still required for the second stage, so the
upregulated adhesionmust be induced by TCR engagement and
may involve cooperation between TCR and CD8 for pMHC
binding.
The Upregulated Adhesion Requires Signaling
The distinctive shape, i.e., a rapid transition from one equilibrium to
another after a 1 s delay, suggests that the two-stage curve may
not be governed solely by the reaction kinetics of the TCR, CD8,
and pMHC molecular triad but may involve other molecules. For
example, the process from the first to the second stage may involve
binding and/or enzymatic kinetics of elements of the signaling
cascade whose (de)phosphorylation may take up some time, giving
rise to a delay. We therefore employed targeted inhibition of key
T cell signaling molecules to test whether they were required for the
upregulatedadhesion.TreatingTcellswithaSrc tyrosinekinase inhib-
itor PP2 (Hanke et al., 1996) resulted in a single-stage pattern (Fig-
ure 3A), suggesting a role for Lck, a Src family protein tyrosine that
associates with CD8 (Davis et al., 2003; Palacios and Weiss, 2004).
As a further confirmation, we inhibited the protein tyrosine phospha-Immunity 34taseCD45,which activates Lckbydephosphorylat-
ing its inhibitory pY505 (Weiss and Littman, 1994;
Zamoyska, 2007). Inhibition of CD45 also abolished
the upregulated adhesion (Figure 3B). In contrast,
two-stage kinetics were unaffected by treatment of
T cells with a Ca2+ chelator BAPTA-AM (Figure 3C),
an inhibitor ofMAP kinase kinase-1 (Figure 3D), and
two inhibitors of PI3 kinase (Figure S2), which repre-
sent signaling events downstream of Lck activity
(Dong et al., 2002; Kane and Weiss, 2003; Wulfing
et al., 1997).
Thus, TCR first binds agonist pMHC to trigger
proximal signaling, which induces a CD8-
dependent adhesion upregulation after a 1 s
delay. This signaling process is downstream ofLck but upstream of Ca2+ fluxes. Note that Ca2+ fluxes can be
triggered by the TCR-pMHC interaction itself and are further
enhanced by the CD8-dependent binding (Delon et al., 1998).
Thus our data reveal a TCR-CD8 positive-feedback loop
involved in the initial steps of the signaling network.
Upregulation of Adhesion by an Anti-CD8
Some anti-CD8 reagents have been reported to enhance T cell
binding to pMHC (Daniels and Jameson, 2000; Devine et al.,
2004; Luescher et al., 1995). Incubating OT1 T cells with one
such monoclonal antibody (mAb), 53-6.7, increased their adhe-
sion to RBCs bearing OVA:H-2Kb to the higher second-stage
level at the shortest contact time tested (Figure 4A, compare
open square and open circle). The use of OVA:H-2Kba3A2 to
prevent CD8 binding eliminated the 53-6.7 mAb-enhanced
adhesion, yielding a lower first-stage level (Figure 4B, open
circle) identical to that obtained without 53-6.7 (Figure 4B,
open triangle). A Fab fragment of 53-6.7 had similar effect as
the whole antibody (compare Figures 4A and 4D, open circle),
thus excluding crosslinking as the cause of enhancement. TCR
binding was also important as indicated by the fact that blocking
with anti-TCR (Figure 4A, open triangle), replacing H-2Kb by
H-2Db (Figure 4C), or using a CD8+TCR hybridoma (Fig-
ure S3A; Yachi et al., 2006) substantially reduced the adhesion
enhanced by 53-6.7. Interestingly, inhibition of Lck with PP2
abrogated the increased adhesion by 53-6.7 (Figure 4D). The
role for Lck was further supported by the finding that the Fab, 13–23, January 28, 2011 ª2011 Elsevier Inc. 15
Figure 3. TCR-Induced CD8-Dependent Increased
Adhesion Can Be Differentially Inhibited
Pa versus t data (measured by the same method as that
in Figure 2) of OT1 (A and B) or F5 (C and D) T cells inter-
acting with pMHC-coated RBCs in the absence (open
square) and presence (open circle) of PP2 (A) (3.5
OVA:H-2Kb/mm2), inhibitor for protein tyrosine phospha-
tase CD45 (B) (14 OVA:H-2Kb/mm2), Ca2+ chelator
BAPTA-AM (C) (32 NP68:H-2Db/mm2), or MAP kinase
kinase-1 inhibitor PD98059 (D) (32 NP68:H-2Db/mm2).
DMSO treatment alone did not inhibit the second-stage
adhesion increment. See also Figure S2.
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TCR-CD8 Cooperation Amplifies pMHC Discriminationfragment of 53-6.7, but not of CT-CD8a, increased Lck activation
(Figure S3B), consistent with previous reports that some anti-
CD8 reagents generate intracellular activation signals resulting
in cytotoxic T cell effector function (Tomonari and Spencer,
1990; Wooldridge et al., 2003). Together, these data suggest
that the antibody 53-6.7 also induced upregulated pMHC
binding by CD8 and TCR, which may share some mechanistic
elements with the second-stage increased adhesion shown in
the preceding section.
TCR Engagement with a Single pMHC Is Sufficient
to Induce Cooperation with CD8
The requirement of direct pMHC binding by both TCR and CD8
suggests a mechanism for the upregulated second-stage adhe-
sion, which might involve signaling-induced cooperation
between TCR and CD8. To test this hypothesis and to assess
the sensitivity of signaling, we took advantage of the single-
bond sensitivity of the micropipette assay (Chesla et al., 1998;
Zhu et al., 2002) by limiting the ligand density to prevent TCR
and CD8 from binding different pMHC molecules. The two
plateau levels changed with the changing pMHC density as
expected from mass action (Figure S4). But the qualitative
patterns remained even when the density was reduced to 3
pMHC/mm2 (Figures 5A and 5B), which predicts a 0.58 mm
average distance between neighboring pMHCs. To achieve
this low density, D-biotin was used to block excess biotin
binding sites on streptavidin bound to RBCs, which minimized
the chance of forming dimeric pMHC by capturing two pMHC16 Immunity 34, 13–23, January 28, 2011 ª2011 Elsevier Inc.th
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amonomers onto the same streptavidin. The re-
sulting first stage had 6% (Figure 5A, open
triangle) or 2% (Figure 5B, open triangle) adhe-
sion frequency only, so that 97% (for OT1) or
99% (for F5) of the measured adhesions were
mediated by single-bond as predicted by Pois-
son distribution (Chesla et al., 1998). Yet, the
second stage was clearly evident, reaching
31% (for OT1) or 16% (for F5) adhesion
frequency (Figures 5A and 5B, open triangle).
Therefore, a single TCR-pMHC bond is suffi-
cient to induce the CD8-dependent upregulated
functional state.
The limited availability of pMHC favors CD8
binding to the pMHC molecules that also inter-
acted with TCR, suggesting trimeric coopera-
tive interaction as a possible mechanism fore upregulated functional state. To further test this hypothesis,
e prevented TCR and CD8 from binding the same pMHC by
oating RBCs with a mixture of OVA:H-2Kba3A2 and vesicular
tomatitis virus (VSV):H-2Kb at various ratios. The former ligand
llowed TCR recognition but not CD8 binding whereas the latter
gand allowed CD8 binding but not TCR recognition. The control
ith a ratio of 100% OVA:H-2Kba3A2 to 0% VSV:H-2Kb (100:0)
howed a single-stage curve (Figure 5C, open square) similar
that shown previously (Figure 2A, open diamond). The 0:100
tio of OVA:H-2Kba3A2 to VSV:H-2Kb abolished binding
igure 5C, open triangle), confirming the requirement for TCR.
portantly, the 5:95 ratio also produced only a single-stage
urve (Figure 5C, open circle). The lack of the second
tage was not due to restricted TCR binding, because the first
tage had 20% adhesions. Nor was it due to the lack of CD8
inding sites, because there were 67 VSV:H-2Kb/mm2 on the
BCs. Thus, our results indicate that it is necessary for TCR
nd CD8 to bind the same pMHC to initiate the upregulated
econd-stage adhesion.
he TCR-CD8 Positive Signaling Feedback Loop
Rapidly Reversible
has recently been reported that TCR signaling could be trig-
ered by applied forces (Kim et al., 2009; Li et al., 2010). To
xclude the possibility that pulling on TCR in repeated contacts
aused the two-stage binding, a ‘‘first-contact’’ experiment was
erformed in which each cell pair was contacted only once. The
dhesion frequency was calculated by dividing the number of
Figure 4. Effect of Anti-CD8 Clone 53-6.7 on T Cell
Adhesion to pMHC and Its Inhibition
Pa versus t data (measured by the same method as that in
Figure 2) of OT1 T cells interacting with RBCs bearing indi-
cated densities of OVA:H-2Kb (A and D), OVA:H-2Kba3A2
(B), or GP33:H-2Db (C) in the absence (open square) or
presence (open circle, open triangle) of the indicated
mAb(s) or inhibitor. Note that the one-order-of-magnitude
higher pMHC density used in (C) than in other panels
translates to an order of magnitude lower binding (average
number of bonds formed per pMHC density) betweenOT1
T cells and RBCs bearing H-2Db than H-2Kb (Experimental
Procedures, Equation 3). See also Figure S3.
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TCR-CD8 Cooperation Amplifies pMHC Discriminationadherent cell pairs by 50 cell pairs tested at each contact
duration. Values at five contact durations were measured with
a total of 250 cell pairs. The result was a two-stage binding curve
indistinguishable from that obtained with 50 repeated contacts
per cell pair and 3–4 cell pairs at each contact duration (Fig-
ure 6A), ruling out the possibility that repeated contacts caused
two-stage kinetics bymechanical stimulation. The data also indi-
cated that the TCR signal required for the second-stage
increased binding was turned off quickly, because it did not
accumulate in the repeated contacts to yield higher adhesion
frequencies than those obtained by single contacts.
We performed two independent experiments to examine how
rapid this activation signal is regulated and how long it sustains.
In the ‘‘long-then-short’’ experiment, a cell pair was first repeat-
edly contacted for a long (>1 s) duration 50 times to estimate
one adhesion frequency and then repeatedly contacted for
a short (<1 s) duration another 50 times to estimate a second
adhesion frequency. Three pairs of long and short durations
were chosen to cover the entire range, resulting in the same
two-stage curve indistinguishable from that obtained with
different cell pairs for different contact durations (Figure 6B).
This suggests the signal triggered by TCR is rapidly reversible
and short-lived.
In the ‘‘alternating’’ experiment, we programmed the adhe-
sion assay by alternating the contact duration between 0.25
and 5 s in 100 repeated contacts (Movie S2). Each test included
a 1.5 s cycling time between the instant when the T cell was re-
tracted away from the RBC to the instant when it was brought
back to contact the RBC again. Adhesions generated by
contacts of the same duration (0.25 or 5 s) were divided by 50
to calculate an adhesion frequency for that contact duration.Immunity 34The two adhesion frequencies so measured
(Figure 6C, solid bars) were significantly
different. However, they were indistinguishable
from the respective adhesion frequencies ob-
tained from 50 consecutive contacts of 0.25
and 5 s (Figure 6C, open bars) for both the
0.25 s and 5 s groups. This result indicates
that the activation signal generated in the 5 s
contact was rapidly turned off within the 1.5 s
cycling time. The activation signal was not
turned on in the next 0.25 s contact because
this duration was too short, but it was turned
on again when the contact duration wasswitched back to 5 s. This rapid reversibility also suggests
that the second-stage binding is not caused by upregulated
expression of CD8 because surface expression is unlikely to
be turned over so fast. The 1 s delay of outset of the second-
stage adhesion enhancement and its elimination by a 1.5 s
contact time gap reveal the speed, duration, and timing of the
signal generation and regulation.
Trimolecular Binding Is Synergistic
Synergy is a hallmark of cooperativity, so we examined whether
TCR-pMHC-CD8 trimolecular interactions generate synergy
over the simple sum of the TCR-pMHC and pMHC-CD8
bimolecular interactions. Because a T cell may adhere to
a pMHC-coated RBC via TCR-pMHC, pMHC-CD8, and/or
TCR-pMHC-CD8 bonds or their combinations, we calculated
the average number of total bonds <n> formed between an
OT1 T cell and a pMHC-coated RBC from the adhesion
frequency and divided it by the ligand density ml to obtain
normalized adhesion bonds <n>/ml (Experimental Procedures,
Equation 4). In our previous experiments where T cell-RBC adhe-
sion was mediated by TCR-pMHC or CD8-pMHC bimolecular
interactions only (Huang et al., 2007, 2010), normalized adhesion
bonds equaled the effective 2D affinity multiplied by the receptor
(TCR or CD8) density (Experimental Procedures, Equation 2).
However, a single affinity is insufficient in the present case
because there are potentially three different types of bonds.
Nevertheless, using normalized adhesion bonds allowed us to
compare the propensities of the TCR-pMHC, pMHC-CD8, and
TCR-pMHC-CD8 interactions for a panel of pMHCs.
For pMHC-CD8 biomolecular interactions (obtained with
TCR blockade), similar curves of normalized adhesion bonds, 13–23, January 28, 2011 ª2011 Elsevier Inc. 17
Figure 5. TCR Engagement with a Single pMHC Is Sufficient to Induce Cooperation with CD8
(A and B) Pa versus t data of OT1 (A) or F5 (B) T cells interacting with RBCs bearing indicated densities of OVA:H-2K
b or NP68:H-2Db. Curves are trend lines.
(C) Pa versus t data of OT1 T cells interacting with RBCs bearing a mixture of OVA:H-2K
ba3A2 and VSV:H-2Kb at indicated ratios but the same total density
(70 sites/mm2). Adhesion frequencies were measured by the same method as that in Figure 2. See also Figure S4.
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TCR-CD8 Cooperation Amplifies pMHC Discriminationwere observed in spite of the variable peptide potencies
(Figures 7A–7F, open triangle), consistent with our previous
report (Huang et al., 2007). For TCR-pMHC bimolecular interac-
tions (obtained with H-2Kba3A2 to abrogate CD8 binding),
widely ranged curves of normalized adhesion bonds were
observed that matched the peptide potencies (Figures 7A–7F,
open circle), also consistent with our previous report (Huang
et al., 2010). Adding these two data sets for each peptide
predicts the normalized adhesion bonds that would have been
formed between OT1 T cells and RBCs bearing wild-type
pMHC without TCR blocking. However, the prediction is based
on the assumption that the TCR-pMHC and pMHC-CD8 bimo-
lecular interactions would have occurred concurrently and inde-Figure 6. Second-Stage Binding Does Not Need Accumulation of Repe
(A) For each contact duration, 50 pairs of F5 T cells and NP68:H-2Db-coated RBC
pairs (open square) to compare with mean Pa ± SEM measured with three to four
circle).
(B) F5 T cells and NP68:H-2Db-coated RBCs (32 mm2) were repeatedly contacte
symbols) and then another 50 times to measure a second Pa at a short duration
measured with cells from the same batch but repeatedly contacted 50 times a
cell pairs) at the first plateau overlap.
(C) Three pairs of F5 T cells and NP68:H-2Db-coated RBCs (23 mm2) were each c
twomeanPa ± SEM (one at each contact duration) by dividing the number of adhes
significantly different (p = 0.0056, Student’s t test). However, no statistical differen
and those measured with 10 pairs of cells from the same batch each consecutiv
18 Immunity 34, 13–23, January 28, 2011 ª2011 Elsevier Inc.pendently, i.e., without cooperation (Experimental Procedures,
Equation 3). Invalidating this assumption, we found that much
higher normalized adhesion bonds were formed between the
OT1 T cells and pMHC-coated RBCs than the predicted simple
sum (Figures 7A–7F and Figure S5, comparing open square and
dashed curves), demonstrating synergy between TCR and CD8
for pMHC binding. Although synergy was observed for all
peptides tested, the resulting normalized adhesion bonds were
much higher for strong ligands than for weak ligands. To
compensate for the low TCR binding propensities of the weak
ligands, substantially higher pMHC densities were used, which
probably increased the chance for CD8 to bind pMHC coopera-
tively with TCR. Thus, cooperation between TCR and CD8 inated Interactions and Is Reversible
s (32 mm2) were each contacted once to estimate Pa from percent adherent
pairs of cells from the same batch each repeatedly contacted 50 times (open
d 50 times first to measure Pa at a long duration (R1 s, indicated by different
(%0.75 s, indicated by matched symbols) (open square) to compare with Pa
t only one duration per pair (open circle). Data (mean ± SEM of three to four
ontacted 100 times with durations alternating between 0.25 and 5 s to measure
ions resulting from contacts of the same duration by 50 (solid bars), whichwere
ces (p > 0.25) were found for both 0.25 and 5 s groups between these Pa values
ely contacted 50 times (open bars). See also Movie S2.
Figure 7. Synergy between TCR and CD8 Amplifies T Cell Discrimi-
nation
(A–F) Pa versus t data (measured by the same methods as that in Figure 2) for
OT1 T cells interacting with RBCs bearing H-2Kb (open square) or H-2Kba3A2
(open circle) complexed with OVA (A), A2 (B), G4 (C), E1 (D), V-OVA (E), and R4
(F). Also presented are datameasured via RBCs bearing H-2Kb in the presence
of the TCR blocking mAb reagent B20.1 (open triange). Pa was converted to
normalized adhesion bonds via Equation 4 (Experimental Procedures) and
presented as mean ± SEM. Dashed curves represent trendlines to the sum
of TCR-pMHC (open circle) and pMHC-CD8 (open triangle) data. See also
Figure S5.
(G) Steady-state (plateau values at 5 s) of the differential normalized adhesion
bonds, D(<n>/mpMHC), formed between OT1 T cells and pMHC-coated RBCs
minus the sum of those formed by the two bimolecular interactions for a panel
of pMHC ligands with increasing potencies.
(H) The differential reciprocal concentrations required to reach half-maximal
T cell proliferation D(1/EC50), measured in the absence of blocking antibody
minus that measured in the presence of Fab of anti-CD8 (CT-CD8a), is plotted
versus D(<n>/mpMHC).
Immunity
TCR-CD8 Cooperation Amplifies pMHC DiscriminationpMHC binding generated synergy to yield much higher numbers
of normalized adhesion bonds than the simple sum of
TCR-pMHC and pMHC-CD8 bimolecular interactions without
cooperation.TCR-CD8 Cooperation Amplifies Peptide Discrimination
To determine the biological relevance of the TCR-CD8 positive-
feedback loop, we examinedwhether the increased propensities
of TCR-pMHC-CD8 trimolecular interactions for a panel of
peptides correspond to the peptide potencies of triggering
T cell responses. The degree of synergy was quantified by the
differential normalized adhesion bonds actually formed between
the T cells and RBCs over the sum of those formed by the TCR-
pMHC and pMHC-CD8 bimolecular interactions, D(<n>/mpMHC)
(Experimental Procedures, Equations 3 and 4). Importantly, the
level of synergy increased with the peptide potency (Figure 7G).
To further define the physiological significance of the TCR-CD8
cooperation, we quantified the differential functional response
resulting from this cooperation. To do this we measured the
reciprocal peptide concentration required to induce half-
maximal T cell proliferation, 1/EC50, without and with CD8 block-
ing (by CT-CD8a Fab), and calculated the difference, D(1/EC50),
resulting from signaling-induced cooperation between TCR and
CD8 for pMHC binding. Remarkably, a strong correlation was
observed in the D(1/EC50) versus D(<n>/mpMHC) plot (Figure 7H),
suggesting that the induced TCR-CD8 cooperation amplifies
peptide discrimination.
DISCUSSION
Effective cytotoxic T cell activation requires engagement of TCR
and contribution of the CD8 coreceptor. By using the micropi-
pette 2D assay to directly measure T cell adhesion to pMHC,
we uncovered two-stage kinetics of a signaling-induced cooper-
ation between TCR and CD8 to enhance binding of agonist
pMHC, which is sensitive to a single ligand. This cooperative
interaction was found to be very fast, short-lived, reversible,
synergistic, and peptide discriminative.
Without cooperation, TCR and CD8 should have interacted
with pMHC concurrently but independently, generating
a single-stage adhesion curve from the addition of two types of
bimolecular bonds (Experimental Procedures, Equation 3) (Zhu
and Williams, 2000). This appeared to be the case for the first
stage of the two-stage curve where the TCR interaction with
agonist pMHC (Huang et al., 2010) dominated because of its
much higher affinity than that of the pMHC-CD8 interaction
(Huang et al., 2007). However, this was not the case for the
second-stage adhesion; many more bonds were formed than
the simple sum of TCR-pMHC plus pMHC-CD8 bonds, thus
revealing cooperative binding that required both TCR and CD8.
Cooperative binding could result in either enhanced biomolec-
ular interactions of TCR-pMHC and/or pMHC-CD8 or trimolecu-
lar complex with coengagement of TCR and CD8 for the same
pMHC. To distinguish these scenarios we prevented TCR and
CD8 from binding different pMHCs by limiting their density.
Two-stage binding was still observed, demonstrating that
binding of TCR and CD8 to the same pMHC was sufficient to
generate cooperation. Using mixed ratios of agonist pMHC en-
coding a mutated CD8 binding site and null pMHC unrecognized
by TCR to force TCR and CD8 to bind distinct pMHCs eliminated
the second stage. This result suggests a spatial relationship
between TCR and CD8 required for binding to the same pMHC
(Gao et al., 1997). The cooperation also raises the possibility
that the coreceptor may directly associate with TCR althoughImmunity 34, 13–23, January 28, 2011 ª2011 Elsevier Inc. 19
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TCR-CD8 Cooperation Amplifies pMHC Discriminationstructural modeling does not seem to support this hypothesis
(Gao et al., 2002; Rudolph et al., 2006). Another possibility is
that TCR and CD8 may be indirectly associated via Lck and/or
other signaling molecules.
Unlike classical cooperative binding, the cooperation between
TCR and CD8 for binding of agonist pMHC is induced. Initial
evidence for induction came from the two-stage curve, where
transition between the first and second stage did not occur until
after a 1 s delay. This was not due to slow pMHC binding kinetics
for TCR and/or CD8 because both the TCR-dominant first stage
and the CD8-dependent second stage rapidly reached equilib-
rium. Rather, the 1 s period may be required for intracellular
signals triggered by TCR engagement to enable TCR and CD8
cooperation. The finding that a single TCR-pMHC bond at the
first stage is sufficient to induce the increased binding in the
second stage highlights the importance of the induced coopera-
tion because T cell responses need to function optimally at low
antigen density.
Asmore definitive evidence, Lck activity was necessary for the
second-stage CD8-dependent adhesion increase, yet its inhibi-
tion did not affect the first-stage TCR-pMHC binding. To further
support the role of Lck, functional CD45, necessary for dephos-
phorylating pY505 to activate Lck, was also required for the
signaling-induced cooperation between TCR and CD8 for
pMHC binding. Lck may act via its interactions with immunore-
ceptor tyrosine-based activation motifs (ITAMs) of CD3. The
initial TCR-pMHC binding may expose some of the CD3 ITAMs
buried in the membrane (Xu et al., 2008) to allow access by
Lck. The action of Lck on CD3 could in turn modify orientation,
conformation, and/or clustering of TCR and/or CD8 at the
membrane to enable their cooperative binding to pMHC. The
enhanced binding further amplifies the Ca2+ and MAPK down-
stream signaling events, although these are not needed for
induced TCR-CD8 cooperation. Thus, the induced cooperation
represents a positive-feedback loop between TCR and CD8 in
the initial signaling events. This is consistent with the proposal
that Lck serves as an adaptor to regulate the interactions of
coreceptors with MHC and TCR (Xu and Littman, 1993). Addi-
tionally, it supports the model that Lck mediates the recruitment
of CD4 or CD8 to the TCR complex upon pMHC recognition as
a means to increase binding (Thome et al., 1995, 1996).
Of interest, the anti-CD8 clone 53-6.7 that improved T cell
binding by pMHC tetramers also induced TCR andCD8 coopera-
tion. Although future studies are required to elucidate how 53-6.7
works, evidence suggests that the 53-6.7 effectsmay share some
mechanistic elements with the TCR-induced CD8-dependent
second-stage increased adhesion. Indeed, H-2Db binding to
CD8 on H-2Kb-restricted OT1 T cells was increased moderately
by 53-6.7, consistent with a change inCD8orientation, conforma-
tion, and/or clustering. Replacing H-2Db by H-2Kb to allow OT1
TCRbinding resulted in a substantial increase in normalizedadhe-
sion bonds to the second-stage level without the 1 s delay. This
would be consistent with TCR-pMHC-CD8 cooperative binding
induced by prebound 53-6.7. Importantly, the Fab fragment of
53-6.7, but not of the control CT-CD8a, increased Lck activation.
Thus, our data have provided insights to the discrepant effects of
some CD8 antibodies on the binding of monomeric (Luescher
et al., 1995) or tetrameric (Holman et al., 2005; Wooldridge
et al., 2003) pMHC by TCR and/or CD8 on T cells.20 Immunity 34, 13–23, January 28, 2011 ª2011 Elsevier Inc.Our recent analysis of TCR-pMHC interactions on the T cell
surface has revealed a strong correspondence between the 2D
binding parameters and T cell responsiveness (Huang et al.,
2010), suggesting that the TCR-pMHC interaction initiates
peptide discrimination. The much higher affinities for agonist
pMHCs (OVA and A2) enable TCR to bind these strong ligands
at low densities and use induced cooperation with CD8 to further
enhance binding. By comparison, 1–2 orders of magnitude
higher densities are required for weak ligands (E1, V-OVA, and
R4) to bind TCR because of the low TCR-pMHC affinities, which
resulted in even fewer normalized adhesion bonds than pMHC-
CD8 interactions (Figures 7D–7F, compare open triangle and
open circle). The substantially higher densities of pMHC may
increase the chance for TCR-CD8 cooperation even in the
classical sense without the 1 s delay to produce more relative
increases in the normalized adhesion bonds (Figure 7, compare
A and B with D–F). However, the induced TCR-CD8 cooperation
produced more absolute increases in the normalized adhesion
bonds for strong ligands than weak ligands (Figure 7G). In fact,
the adhesion enhancements for a panel of pMHC ligands match
the corresponding enhancements in T cell responses, suggest-
ing an additional level of peptide discrimination. It is reasonable
to hypothesize that different initial TCR-pMHC binding charac-
teristics have to be converted into differential biological signals,
be amplified by the signaling cascade, and pass some fidelity
checkpoints before committing the T cell to distinct responses.
Our results thus reveal a mechanism for TCR-induced coopera-
tion with CD8 to amplify the initial discriminative signals by posi-
tive feedback.EXPERIMENTAL PROCEDURES
Reagents
Naive CD8+ T cells of OT1 or F5 TCR transgenic mice (Huang et al., 2007) and
MOG-reactive CD4+ T cells (Ford and Evavold, 2003) were generated with
Emory University IACUC-approved protocols. CD8+TCR OT1 hybridoma
(Yachi et al., 2006) was from N.R. Gascoigne (Scripps Research Institute).
The following peptides were synthesized: ovalbumin-derived peptides OVA,
A2, G4, E1, V-OVA, and R4, and a vesicular stomatitis virus-derived peptide
VSV (Alam et al., 1996; Huang et al., 2010) as well as the influenza virus
nucleoprotein-derived peptide NP68 (Smyth et al., 2002) and the lymphocytic
choriomeningitis virus-derived peptide GP33 (Kerry et al., 2003). Monomeric
mouse pMHC-I (OVA, A2, G4, E1, V-OVA, R4, or VSV on H-2Kb or
H-2Kba3A2 and NP68 or GP33 on H-2Db) and pMHC-II (MOG38-49:I-Ab)
(Sabatino et al., 2008) with C-terminal biotin tags were produced by the NIH
Tetramer Core Facility.
PE-conjugated/-unconjugated anti-mouse TCR Va2 (B20.1) and Vb 11
(RR3-15) were from BD Biosciences (San Jose, CA), and CD8a (CT-CD8a)
and CD8b (CT-CD8b) mAbs were from Invitrogen (Carlsbad, CA). Anti-mouse
CD8 clone 53-6.7 was from eBioscience (San Diego, CA). Anti-mouse H-2Kb
(3H2672, PE-conjugated) and H-2Db (BCDb, FITC-conjugated) were from
US Biological (Swampscott, MA) and Biocarta (San Diego, CA), respectively.
Anti-biotin (Bio3-18E7.2, PE-conjugated) was from Miltenyi Biotec (Auburn,
CA). Anti-mouse Lck pY394 (9A6) was from Milliore (Billerica, MA). PE-conju-
gated goat anti-mouse was from Sigma-Aldrich (St. Louis, MO). Fab fragments
of mAbs were prepared with a kit according to the manufacturer’s instruction
(Pierce, Rockford, IL).
PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) was
from Biomol (Plymouth Meeting, PA). Protein tyrosine phosphatase CD45
inhibitor (N-(9, 10-Dioxo-9, 10-dihydro-phenanthren-2-yl)-2, 2-dimethyl-pro-
pionamide), intracellular calcium chelator BAPTA-AM, MAP kinase kinase-1
inhibitor PD98059, and PI3 kinase inhibitor Ly294002 and wortmanin were
from EMD (San Diego, CA).
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RBCs were isolated with a Georgia Institute of Technology IRB-approved
protocol as described (Chesla et al., 1998). To coat different pMHC densi-
ties, RBCs were biotinylated with Biotin-X-NHS (EMD) at different concentra-
tions as described (Huang et al., 2007). Biotinylated RBCs were incubated
with excess streptavidin (EMD or Pierce) for 30 min and with saturating
amount of pMHC for another 30 min after removing unbound streptavidin.
To achieve low pMHC densities and prevent dimeric pMHC formation,
excessive biotin binding sites were partially blocked by D-biotin (Sigma-
Aldrich). To separate TCR and CD8 binding sites on distinct pMHC mono-
mers, RBCs were incubated with saturating amount of OVA:H-2Kba3A2
and VSV:H-2Kb at a 5:95 ratio. Tetrameric streptavidin has four biotin bind-
ing sites, two on each side. One side binds the biotinylated RBC and
the other side binds pMHC or D-biotin. The 5:95 ratio predicts 0.2% of
OVA:H-2Kba3A2/OVA:H-2Kba3A2 homodimers, 9.6% of OVA:H-2Kba3A2/
VSV:H-2Kb heterodimers, and 90.2% VSV:H-2Kb/VSV:H-2Kb homodimers
on the same streptavidin.
Site Density and Lck Activation Measurements
The densities of pMHC, TCR, and CD8 were determined as described (Huang
et al., 2007). To evaluate Lck activation by 53-6.7, OT1 T cells were incubated
in modified flow cytometry buffer (PBS+5% FCS+0.02% NaN3) with 10 mg/ml
Fab of 53.6.7 or control mAb (CT-CD8a) and 50 mg/ml anti-TCR (B20.1) for
30 min at 4C. Cells were fixed by 4% paraformaldehyde, incubated with
10 mg/ml anti-Lck pY394 in SAP buffer (HBSS+0.1% saponin+0.05%
NaN3+5% FBS), stained with a PE-conjugated secondary antibody, resus-
pended in modified flow cytometry buffer, and analyzed by flow cytometry.
Adhesion Frequency Assay
This assay has been described (Chesla et al., 1998; Huang et al., 2010). In brief,
a T cell and a RBCwere aspirated by respective pipettes (Figure 1A) and driven
in and out of contact with controlled area and duration. Adhesion was
observed from stretching of the RBC on T cell retraction. This contact-retrac-
tion cycle was either repeated 50 times for a given contact duration (Movie S1)
or alternated between two contact durations for 100 times (Movie S2) on each
cell pair, and 3–5 cell pairs were used to estimate an adhesion frequency
Pa (mean ± SEM). Experiments were performed at 25
C (most cases) or
37C (indicated). In some experiments, T cells were pretreated for 30 min at
25C (for mAbs) or 37C (for inhibitors) with 10 mg/ml CD8 blocking (CT-CD8a)
or activating (53-6.7) mAb or equivalent amount of their Fab, 50 mg/ml TCR Va2
(B20.1, for blocking the OT1 TCR) or 25 mg/ml Vb 11 (RR3-15, for blocking the
F5 TCR) mAb, 10 mM protein tyrosine phosphatase CD45 inhibitor, 50 mM
PD98059, 10 mM Ly294002, or 100 nM wortmannin, and the experiments
were performed in the continuous presence of these agents. To inhibit Src
family kinases, T cells were preincubated with 10 mM PP2 for 10 min at 25C
and tested in the next 10 min with continuous presence of PP2. For chelating
Ca2+, T cells were preloadedwith 50 mMof BAPTA-AM for 20min at 37C in the
presence of 1 mM EGTA and with 1 mM EGTA supplemented to chamber
medium.
Calculating Effective 2D Affinity and Synergy
The adhesion frequency Pa is related to the average bond number <n> by
Pa = 1 expð<n>Þ: (1)
When adhesion is mediated by a single receptor-ligand specie and Pa has
reached a plateau,
<n>=mrmlAcKa; (2)
where mr and ml are receptor and ligand densities (Chesla et al., 1998).
The product of the contact area Ac (a few percents of 3 mm
2, kept constant
in experiments) and binding affinity Ka is called effective 2D affinity (in mm
4).
For adhesion mediated by dual receptor-ligand species, e.g., TCR and CD8,
<n> includes contributions from both species and is expressed at a per
pMHC density basis as the sum of two bimolecular interactions (Zhu and
Williams, 2000
<n>=mpMHC =mTCRAcKaCD8 +mCD8AcKaCD8; (3)provided that TCR and CD8 bind pMHC concurrently and independently.
However, Equation 3 no longer applies if TCR and CD8 bind pMHC coopera-
tively. Nevertheless, Pa can be converted to <n> and divided by ligand density
to obtain normalized adhesion bonds,
<n>=mpMHC =  lm½1 PaðplateauÞ=mpMHC: (4)
The level of synergy can be calculated from the difference between
<n>/mpMHC determined with the TCR-pMHC-CD8 trimolecular Pa and the
sum of <n>/mpMHC values determined with the TCR-pMHC and pMHC-CD8
bimolecular Pa’s.
Quantifying Peptide Potency
Naive OT1 splenocytes (3 3 105/well) were cultured in 96-well plates with the
desired peptide at 37C in the absence or presence of 10 mg/ml anti-CD8
(CT-CD8a) Fab. After 48 hr, 0.4 mCi/well of [3H]thymidine was added. After
another 18 hr, cells were harvested on a FilterMate harvester (PerkinElmer)
and analyzed on a Matrix 96 Direct Beta Counter (PerkinElmer). EC50 values
were calculated with GraphPad Prism.
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